Literature DB >> 20141344

A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG.

Rolf Svedjeholm1, Mårten Vidlund, Ingemar Vanhanen, Erik Håkanson.   

Abstract

OBJECTIVE: Adverse outcome after CABG is closely related to postoperative heart failure precipitated by ischemia and myocardial infarction. Restrictive use of inotropes is therefore desirable. Patients with preoperative left ventricular dysfunction are a high-risk group in this respect. To reduce myocardial oxygen expenditure we evolved a metabolic strategy for perioperative care.
DESIGN: Observational study on 104 consecutive patients with severe left ventricular dysfunction undergoing CABG. The metabolic strategy implied physiological measures to minimize myocardial oxygen expenditure including restrictive use of inotropes and specific measures such as extended CPB and metabolic support to facilitate myocardial recovery. Hemodynamic state was primarily assessed by mixed venous oxygen saturation (SvO(2)). Follow-up averaged 9.7+/-1.4 years.
RESULTS: LVEF was 0.30+/-0.05 (range 0.20-0.37) and 3.5+/-1.3 vessels were bypassed. Inotropes were used in 6.7% for weaning from CPB. Increase of s-creatinine by > or =50% compared to preoperative values was observed in 2.9%. Logistic EuroSCORE was 8.3% whereas observed 30-day mortality was 1.0%. Crude 5-year survival was 89.4%.
CONCLUSIONS: The metabolic strategy allowed restrictive use of inotropes and was associated with encouraging long-term survival. Renal function was well preserved suggesting that SvO(2) served as an adequate marker of circulation. Randomized trials with metabolic support are warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20141344     DOI: 10.3109/14017430903531008

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  5 in total

1.  Central venous oxygen saturation during cardiopulmonary bypass predicts 3-year survival.

Authors:  Staffan Svenmarker; Sören Häggmark; Margareta Östman; Anders Holmgren; Ulf Näslund
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-12

2.  Post hoc analysis of the glutamics-trial: intravenous glutamate infusion and use of inotropic drugs after cabg.

Authors:  Mårten Vidlund; Bashir Tajik; Erik Håkanson; Örjan Friberg; Jonas Holm; Farkas Vanky; Rolf Svedjeholm
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

3.  Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.

Authors:  Jonas Holm; Gabriele Ferrari; Anders Holmgren; Farkas Vanky; Örjan Friberg; Mårten Vidlund; Rolf Svedjeholm
Journal:  PLoS Med       Date:  2022-05-09       Impact factor: 11.613

4.  Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study.

Authors:  Huiqi Jiang; Jonas Holm; Örjan Friberg; Farkas Vanky; Mårten Vidlund; Bashir Tajik; Yanqi Yang; Rolf Svedjeholm
Journal:  Perioper Med (Lond)       Date:  2021-07-13

5.  The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.

Authors:  Huiqi Jiang; Jonas Holm; Mårten Vidlund; Farkas Vanky; Örjan Friberg; Yanqi Yang; Rolf Svedjeholm
Journal:  J Transl Med       Date:  2020-05-11       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.